EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral blood‐derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients

Benedikt Asey, Tobias F Pantel, Malte Mohme, Yahya Zghaibeh, Lasse Dührsen, Dana Silverbush, Ulrich Schüller iD, Richard Drexler, Franz L Ricklefs iD

Brain Pathology · 2025

DOI: 10.1111/bpa.13334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Pathology, 2025. Verfasst von Benedikt Asey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, DNA Methylation, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Illumina Inc, Fördergemeinschaft Kinderkrebszentrum Hamburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastomas are known for their immunosuppressive tumor microenvironment, which may explain the failure of most clinical trials in the past decade. Recent studies have emphasized the significance of stratifying glioblastoma patients to predict better therapeutic responses and survival outcomes. This study aims to investigate the prognostic relevance of peripheral immune cell counts sampled prior to surgery, with a special focus on methylation‐based subclassification. Peripheral blood was sampled in patients with newly diagnosed ( n = 176) and recurrent ( n = 41) glioblastoma at the time of surgery and analyzed for neutrophils, monocytes, leukocytes, platelets, neutrophil–lymphocyte ratio, lymphocyte–monocyte ratio, and platelet–lymphocyte ratio. Peripheral immune cell counts were correlated with patients' survival after combined radiochemotherapy. In addition, 850 k genome‐wide DNA methylation was assessed on tissue for defining tumor subclasses and performing cell‐type deconvolution. In newly diagnosed glioblastoma, patients with higher peripheral neutrophil counts had an unfavorable overall survival (OS) ( p = 0.01, median overall‐survival (mOS) 17.0 vs. 10.0 months). At the time of first recurrence, a significant decrease of peripheral immune cell counts was observed, and elevated monocyte ( p = 0.03), neutrophil ( p = 0.04), and platelet ( p = 0.01) counts were associated with poorer survival outcomes. DNA methylation subclass‐stratified analysis revealed a significant survival influence of neutrophils ( p = 0.007) and lymphocytes ( p = 0.04) in the mesenchymal (MES) subclass. Integrating deconvolution of matched tumor tissue showed that platelets and monocytes were correlated with a more differentiated, tumor‐progressive cell state, and peripheral immune cell counts were most accurately reflected in tissue of the MES subclass. This study illustrates a restricted prognostic significance of peripheral immune cell counts in newly diagnosed glioblastoma and a constrained representation in matched tumor tissue, but it demonstrates a more pertinent situation at the time of recurrence and after DNA methylation‐based stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDNA MethylationBrain NeoplasmsHumansFemaleMaleMiddle AgedPrognosisAgedAdultMonocytesTumor MicroenvironmentNeutrophilsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

composite scoreglioblastomaimmunemethylationoutcomeprognosis

Autor:innen und Institutionen

  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Pediatric Hematology and Oncology, Research Institute Children's Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.

ORCID-Profile: Ulrich Schüller, Franz L Ricklefs

Förderung

  • Deutsche Forschungsgemeinschaft
  • Illumina Inc
  • Fördergemeinschaft Kinderkrebszentrum Hamburg

Zitieren

APA

Asey, B., Pantel, T. F., Mohme, M., Zghaibeh, Y., Dührsen, L., Silverbush, D., Schüller, U., Drexler, R., & Ricklefs, F. L. (2025). Peripheral blood‐derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients. Brain Pathology. https://doi.org/10.1111/bpa.13334

Vancouver

Asey B, Pantel TF, Mohme M, Zghaibeh Y, Dührsen L, Silverbush D, et al. Peripheral blood‐derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients. Brain Pathology. 2025. doi:10.1111/bpa.13334

BibTeX
@article{Asey2025,
  author = {Asey, Benedikt and Pantel, Tobias F and Mohme, Malte and Zghaibeh, Yahya and Dührsen, Lasse and Silverbush, Dana and Schüller, Ulrich and Drexler, Richard and Ricklefs, Franz L},
  title = {Peripheral blood‐derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients},
  journal = {Brain Pathology},
  year = {2025},
  doi = {10.1111/bpa.13334}
}
Kostenlos starten →